Purchase Order 75N95024P00039
Award Date
11/28/23
Potential Completion Date
11/28/24
Potential Value
$108K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health within the Department of Health and Human Services, to Pharmaron, Inc. for $64,090. The contract is for Pharmaron to conduct a 14-day dose range-finding toxicity study in male and female rats to determine the maximally tolerated dose of an investigational molecule under development by NCATS. Specifically, Pharmaron will test the...
The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $39,060 firm fixed price purchase order to Pharmaron, Inc. to evaluate absorption, distribution, metabolism, and excretion of compounds from an NIH dystonia research project. Per the sole source solicitation, Pharmaron will leverage its unique experience with the class of compounds to provide consistency and reproducibility in the evaluation process, compare new analogs to previous ones in the same...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...
This firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Pharmaron, Inc., a minority-owned for-profit contract research organization, to conduct Good Laboratory Practice (GLP) toxicity studies in rats and dogs. The $102,250.00 contract supports the Institute's Investigational New Drug (IND) enablement project, with Pharmaron performing services such as...
This is a federal contract award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for the pharmaceutical and biotechnology industries, as well as government agencies. The contract was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), and is part of the NIH Bioanalysis Testing Services 2015-2020 master indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract...